- Home
- CBFV vs SGMT Comparison
CBFV vs SGMT Comparison
Compare CBFV & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CBFV | SGMT |
|---|---|---|
| Founded | 1901 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.7M | 169.4M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CBFV | SGMT |
|---|---|---|
| Price | $35.82 | $6.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $38.00 | $26.13 |
| AVG Volume (30 Days) | 6.8K | ★ 1.3M |
| Earning Date | 04-22-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $43,557,000.00 | $2,000,000.00 |
| Revenue This Year | $48.93 | N/A |
| Revenue Next Year | $7.97 | N/A |
| P/E Ratio | $49.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.00 | $4.50 |
| 52 Week High | $38.86 | $10.46 |
Technical Indicators
Market Signals| Indicator | CBFV | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 47.42 |
| Support Level | $34.06 | $7.04 |
| Resistance Level | $36.44 | $7.39 |
| Average True Range (ATR) | 0.71 | 0.44 |
| MACD | -0.20 | -0.08 |
| Stochastic Oscillator | 17.71 | 21.77 |
Price Performance
Historical ComparisonAbout CBFV CB Financial Services Inc.
CB Financial Services Incis a bank holding company headquartered in Carmichaels, Pennsylvania. The company had one reportable segment, community banking services. The Bank also has a loan production office in Allegheny County, a loan production office and a corporate center in Washington County, and an operations center in Greene County, Pennsylvania. The Bank is a community-oriented institution offering residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a variety of deposit products for individuals and businesses in its market area.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.